

Clobetasol pretreatment to reduce and prevent injection site dermatitis from biologic agents



Deede Liu, MD, Dominic J. Wu, MD, Anand Rajpara, MD, Ting Wang, MD, and Daniel J. Aires, MD, JD
Kansas City, Kansas

Key words: adverse reactions; biologic agents; clobetasol propionate; injection site dermatitis; prevention of injection site dermatitis.

THERAPEUTIC CHALLENGE

Although anti-tumor necrosis factor and other biologic agents have shown success in controlling distressing dermatologic conditions, such as psoriasis and hidradenitis suppurativa, 12%-37% of patients have injection site reactions that can decrease effectiveness and adherence to therapy.¹⁻³

SOLUTION

To mitigate or prevent injection site reactions, clobetasol propionate 0.05% ointment can be applied to the injection site once a day beginning 2 days in advance of the biologic therapy injection. Intermittent short-term clobetasol treatment carries minimal risk. Our clinic has implemented this strategy and has seen successful mitigation and prevention of biologic injection site reactions. Reducing injection site reactions appears to improve patient satisfaction and increase adherence to drug regimens. Although reducing reactions might also reduce loss of efficacy, we do not have data on this.

REFERENCES

1. Kaushik SB, Lebwohl MG. CME part I psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. *J Am Acad Dermatol*. 2019;80:27-40.
2. Sorenson E, Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. *J Dermatolog Treat*. 2015;26(6):493-501.
3. Warren RB, Smith CH, Yiu ZZ, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). *J Invest Dermatol*. 2015;135(11):2632-2640.

From the University of Kansas Medical Center, Division of Dermatology, Kansas City.

Funding sources: None.

Conflicts of interest: None disclosed.

Reprint requests: Daniel J. Aires, MD, JD, Division Director, Division of Dermatology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160. E-mail: daires@kumc.edu.

J Am Acad Dermatol 2019;80:e71.

0190-9622/\$36.00

© 2018 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2018.09.001>